Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Merck Manual of Diagnosis and Therapy Stories

2013-12-18 12:25:31

DARMSTADT, Germany, December 18, 2013 /PRNewswire/ -- - New agreement aims to translate CNIO research into new potential treatment options for cancer patients - License agreement encompasses two series of ATR inhibitors and a screening platform Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre (CNIO) in Madrid in the...

2013-11-15 04:21:05

DARMSTADT, Germany and NANTONG, China, November 15, 2013 /PRNewswire/ -- - EUR 80 million investment underscores Merck's long-term commitment to China - New facility will focus on Merck's leading brands referenced in China's essential drug list and serve the country's expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders Merck announced today a EUR 80 million investment in a...

2013-11-13 04:22:57

DARMSTADT, Germany, November 13, 2013 /PRNewswire/ -- - New agreement marks the second collaboration between Merck and BeiGene Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China. The compound, which is a potent poly (ADP-ribose) polymerase (PARP)...

2013-09-30 08:29:27

SUMMIT, N.J., Sept. 30, 2013 /PRNewswire/ -- HomeAgain(®) Pet Recovery Service, a division of Merck Animal Health, today announced the five finalists for the HomeAgain Hero of the Year Award. Chosen by an esteemed panel of judges from the animal welfare community, each finalist was identified as having outstanding dedication to supporting the health and well-being of companion animals. "We received hundreds of nominations detailing countless ways people are contributing to and making a...

2013-08-01 08:34:47

Program Encourages Women to Plan their Future WHITEHOUSE STATION, N.J., Aug. 1, 2013 /PRNewswire/ -- On- or off-campus housing? Which major to declare? An internship or work study? These are questions often debated by college-aged women at the start of a new school year. One question that they may not be asking themselves is, "how will the decisions I make today impact my future?" This year, as college women prepare to head back to school, Merck (known as MSD outside the United...

2013-05-06 08:26:45

The Active Family Project, Together with Celebrity Mom Elisabeth Hasselbeck, Kicks Off First Annual National Family Playdate on May 11 WHITEHOUSE STATION, N.J., May 6, 2013 /PRNewswire/ -- Merck Consumer Care, the consumer products division of Merck (NYSE: MRK) announced today the launch of the Active Family Project, a new health and wellness initiative in the U.S. focused on reaching women who actively manage the well-being of their families and themselves. The Active Family Project...

2013-05-01 08:27:42

Merck's Bridgette P. Heller receives cover feature, exclusive behind-the-scenes interview and photographs NEW YORK, May 1, 2013 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's April cover story profiles Bridgette P. Heller, executive vice president at Merck, president of Merck Consumer Care and the Healthcare Businesswomen's Association (HBA) 2013 Woman of the Year. For the sixth year in a row, PHARMACEUTICAL EXECUTIVE, the industry's premier publication, highlights HBA's choice...

2013-03-26 08:26:16

NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly magazine and daily online publication of record on analytics, trends and personalities in the biopharmaceutical industry worldwide, announced today the choice for its 2013's drug Brand of the Year: Merck's Januvia [sitagliptin], a first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type II] diabetes. Brand of the Year is an independent, non-promotional designation, selected annually since...

2013-03-07 08:29:33

NEW YORK, March 7, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Novartis AG (NYSE: NVS), and GlaxoSmithKline Plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report Since the...

2013-02-14 08:30:41

HEERLEN, Netherlands and AMSTERDAM, Feb. 14, 2013 /PRNewswire/ -- The Dutch pension fund Stichting Pensioenfonds ABP ("ABP"), together with three co-lead plaintiffs, has reached a settlement with Merck and certain of its current and former officers and directors, whereby Merck will pay $215 million to resolve a five-year-old securities class action against all of the Merck defendants. This settlement is part of a $688 million total settlement that Merck agreed to with plaintiffs in two class...